Sign in

CIK 0001662774

  • Non-accelerated filer
  • Smaller reporting company

IRulya Therapeutics Inc.

Sign in to watch
Ticker
IRLA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
901024039
Phone
+1 203-208-8994
Business address
101 COLLEGE STREET, SUITE 210, NEW HAVEN, CT, 06510
Former names
Quince Therapeutics, Inc., Cortexyme, Inc.
  1. 4 Open-market buy Director bought 50,000 shares at $33.77 ($1,688,500)
  2. 4 Gift Director gave 1,534,720 shares (gift)
  3. 4 Open-market sale Chief Executive Officer sold 30,000 shares at an average $35.59 ($1,067,611)
  4. 4 Open-market buy Director bought 50,000 shares at an average $35.34 ($1,767,057)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Derivatives Options or other derivatives
  8. 4 Open-market sale Chief Executive Officer sold 60,000 shares at an average $38.49 ($2,309,600)
  9. 5 Insider Annual Insider Trading Report
  10. 4 Open-market sale Executive Vice President sold 40,000 shares at an average $30.81 ($1,232,528)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Exercise or conversion Executive Vice President acquired 3,500 shares (option exercise)
  17. 4 Open-market buy IA/Managing Member of 10% Owne bought 9,040 shares at an average $44.25 ($400,018)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 8 of 11 · 211 filings